RT-LAMP has high accuracy for detecting SARS-CoV-2 in saliva and naso/oropharyngeal swabs from asymptomatic and symptomatic individuals

*†Stephen P. Kidd[1,2], †Daniel Burns[1,3], Bryony Armson[1,2,4], Andrew D. Beggs[5], Emma L. A. Howson[6], Anthony Williams[7], Gemma Snell[7], Emma L. Wise[1,8], Alice Goring[1], Zoe Vincent-Mistiaen[9], Seden Grippon[1], Jason Sawyer[10], Claire Cassar[10], David Cross[10], Tom Lewis[10], Scott M. Reid[10], Samantha Rivers[10], Joe James[10], Paul Skinner[10], Ashley Banyard[10], Kerrie Davies[11], Anetta Ptasinska[5], Celina Whalley[5], Jack Ferguson[5], Claire Bryer[5], Charlie Poxon[5], Andrew Bosworth[5], Michael Kidd[5,12], Alex Richter[13], Jane Burton[14], Hannah Love[14], Sarah Fouch[1], Claire Tillyer[1], Amy Sowood[1], Helen Patrick[1], Nathan Moore[1], Michael Andreou[15], Shailen Laxman[15], Nick Morant[16], Duncan Clark[16], Charlotte Walsh[16], Rebecca Houghton[1], Joe Parker[17], Joanne Slater-Jefferies[17], Ian Brown[10], Zandra Deans[2], Deborah Porter[2], Nicholas J. Cortes[1,9], Keith M. Godfrey[18,19], Angela Douglas[2], Sue L. Hill[2], Veronica L. Fowler[1,2]

[1]Hampshire Hospitals NHS Foundation Trust, Department of Microbiology, Basingstoke and North Hants Hospital, Basingstoke, UK

[2]NHS Test and Trace Programme, Department of Health and Social Care, UK

[3]School of Electronics and Computer Science, University of Southampton, UK

[4]vHive, School of Veterinary Medicine, University of Surrey, Guildford, UK

[5]University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK

[6]The Pirbright Institute, Ash Road, Pirbright, Woking, UK

[7]University of Southampton & Division of Specialist Medicine, University Hospital Southampton, UK

[8]School of Biosciences and Medicine, University of Surrey, Guildford, UK

[9]Gibraltar Health Authority, Gibraltar, UK

[10]Animal and Plant Health Agency, New Haw, Addlestone, Surrey, UK

[11]Leeds Teaching Hospitals NHS Trust and University of Leeds, UK

[12]Public Health West Midlands Laboratory, Birmingham, UK

[13]Institute of Immunology and Immunotherapy, University of Birmingham, UK

[14]High Containment Microbiology, National Infection Service, Public Health England, Porton Down, UK

[15]OptiSense Limited, Horsham, West Sussex, UK

[16]GeneSys Biotech Limited, Camberley, Surrey, UK

[17]National Biofilms Innovation Centre, University of Southampton, UK

[18]NIHR Southampton Biomedical Research Centre, University of Southampton and University Hospital, UK

[19]MRC Lifecourse Epidemiology Unit, University of Southampton, UK

*Corresponding author: - stephen.kidd@hhft.nhs.uk, †Denotes co-first authorship

38 **Abstract**

39 To validate an improved sample preparation method for extraction free Direct RT-LAMP and define
40 the clinical performance of four different RT-LAMP assay formats for detection of SARS-CoV-2 with a
41 multisite clinical evaluation.

42 **Method**

43 We describe Direct RT-LAMP on 559 swabs and 86,760 saliva samples and RNA RT-LAMP on extracted
44 RNA from 12,619 swabs and 12,521 saliva samples collected from asymptomatic and symptomatic
45 individuals across multiple healthcare and community settings.

46 **Results**

47 For Direct RT-LAMP, we found a diagnostic sensitivity (DSe) of 70.35% (95% CI 63.48-76.60%) on swabs
48 and 84.62% (79.50-88.88%) on saliva, with diagnostic specificity (DSp) of 100% (98.98-100.00%) on
49 swabs and 100% (99.72-100.00%) on saliva when compared to RT-qPCR. Analysing samples with RT-
50 qPCR ORF1ab C_T values of $\leq$25 and $\leq$33 (high and medium-high viral copy number, respectively), we
51 found DSe of 100% (96.34-100%) and 77.78% (70.99-83.62%) for swabs, and 99.01% (94.61-99.97%)
52 and 87.32% (80.71-92.31%) for saliva. For RNA RT-LAMP DSe and DSp were 95.98% (92.74-98.06%)
53 and 99.99% (99.95-100%) for swabs, and 80.65% (73.54-86.54%) and 99.99% (99.95-100%) for saliva,
54 respectively.

55 **Conclusions**

56 The findings from these evaluations demonstrate that RT-LAMP testing of swabs and saliva is
57 applicable to a variety of different use-cases, including frequent, interval-based testing of saliva from
58 asymptomatic individuals via Direct RT-LAMP that may otherwise be missed using symptomatic testing
59 alone.

60

61

62 **Introduction**

63 Rapid diagnostic testing to identify and isolate symptomatic and asymptomatic individuals
64 potentially transmitting infectious viral pathogens is an essential requirement of any pandemic
65 response. The novel *betacoronavirus*, SARS-CoV-2, initially identified after an outbreak of viral
66 pneumonia in Wuhan, China in December 2019(1), has rapidly spread throughout the world, causing
67 over 141 million confirmed cases and over 3.1 million deaths(2), (April, 2021).

68 Conventional diagnostics for SARS-CoV-2 consist of RNA enrichment followed by reverse-
69 transcriptase quantitative real-time PCR (RT-qPCR) against one or more viral gene targets(3).
70 However, this methodology requires sample inactivation, RNA extraction and RT-qPCR thermal
71 cycling, meaning that the time from sample-to-result can often be several hours, and requires
72 centralised equipment and personnel trained in Good Laboratory Practice to perform testing.

73 We have previously shown the utility of reverse-transcriptase loop mediated isothermal
74 amplification (RT-LAMP) for the detection of SARS-CoV-2 both from extracted RNA (RNA RT-LAMP)
75 and directly from nasopharyngeal/oropharyngeal swabs (Direct RT-LAMP)(4). RT-LAMP utilises a
76 rapid and stable DNA polymerase that amplifies target nucleic acids at a constant temperature. This
77 removes the requirement for conventional thermal cycling allowing RT-LAMP reactions to be
78 performed in shorter reaction times using less sophisticated platforms.

79 In a study of 196 clinical samples(4), testing of RNA extracted from nasopharyngeal/oropharyngeal
80 swabs collected into viral transport media (VTM) using RNA RT-LAMP demonstrated a diagnostic
81 sensitivity (DSe) of 97% and a diagnostic specificity (DSp) of 99% in comparison to RT-qPCR of the
82 ORF1ab region of SARS-CoV-2. For Direct RT-LAMP on crude swab samples, the DSe and DSp were
83 67% and 97%, respectively. When a cycle threshold (C_T) cut-off for RT-qPCR of < 25 was considered,
84 reflecting the increased likelihood of detecting viral RNA from active viral replication, the DSe of
85 Direct RT-LAMP increased to 100% (4).

However, the collection of a swab sample is invasive and during the time of the pandemic there have been considerable shortages in swab supplies. Exploring the use of alternative sample types that are both easy to collect and more of a comfortable from a sampling perspective is desirable particularly when repeat sampling is performed. Saliva presents an ideal bio-fluid that fulfils both these objectives and previous studies have shown that SARS-CoV-2 is readily detectable in such a sample type(5–10). To improve the diagnostic sensitivity of previously described saliva Direct RT-LAMP(4), optimisation of saliva preparation for the detection of SARS-CoV-2 was undertaken utilising a cohort of 3100 saliva samples from an asymptomatic population(11) of healthcare workers; where saliva was diluted 1:1 in Mucolyse™, followed by a 1 in 10 dilution in 10% (w/v) Chelex© 100 Resin ending with a 98°C heat step prior to RT-LAMP which resulted in optimal sensitivity and specificity.

Despite the benefits of this optimisation, the protocol added additional steps and reagents which increased chance for user error and made the automation of the process more challenging. We therefore aimed to investigate a simpler process using a novel reagent, RapiLyze (OptiGene Ltd), which is a sample dilution buffer, followed by a two-minute heat-step. This novel sample preparation method was evaluated in combination with Direct RT-LAMP using samples collected from symptomatic National Health Service (NHS) patients and symptomatic and asymptomatic healthcare staff.

104 **Methods**

105 **Testing sites**

106 The OptiGene Ltd. SARS-CoV-2 RT-LAMP assay was evaluated in nine sites, comprising Basingstoke
107 and North Hampshire Hospital & Royal Hampshire County Hospital, Hampshire Hospitals NHS
108 Foundation Trust; University Hospital Southampton; Animal and Plant Health Agency/MRC
109 Lifecourse Epidemiology Unit (University of Southampton); Public Health Lab Manchester/CMFT;
110 Leeds Teaching Hospitals NHS Trust; University Hospitals Birmingham NHS Foundation
111 Trust/Institute of Cancer & Genomic Science University of Birmingham; High Containment
112 Microbiology, National Infection Service, Public Health England, Porton Down and Public Health
113 University Laboratory, Gibraltar Health Authority, Gibraltar, UK.

114 **Clinical samples**

115 Nasopharyngeal and oropharyngeal swabs were collected from asymptomatic and symptomatic
116 individuals and placed in viral transport media (VTM).

117 Drooled saliva samples were collected at the start of the day; prior to eating, drinking, teeth
118 brushing, or using a mouthwash. Saliva was transferred into the specimen pot directly or via a clean
119 teaspoon, according to a standardised protocol. Samples from UHB deposited saliva straight into the
120 collection pot.

121

122 **RNA extraction**

123 RNA was extracted using a range of different methods available at each participating site:

124 *Maxwell® RSC Viral Total Nucleic Acid Purification Kit*

125 In a class 1 microbiological safety cabinet (MSC) within a containment level 3 laboratory, 200 µl of
126 sample was added to 223 µl of prepared lysis solution (including 5 µl per reaction of Genesig® Easy

127 RNA Internal extraction control, Primerdesign Ltd, Chandler's Ford, UK). Samples were then
128 inactivated for 10 minutes at room temperature within the MSC and 10 minutes at 56°C on a heat
129 block before automated RNA extraction using a Maxwell® RSC48 Instrument (Promega UK Ltd.,
130 Southampton, UK). RNA was eluted in 50 µl of nuclease-free water (NFW).

131 *MagMAX™CORE Nucleic acid 140 purification kit*

132 10 µl of sample (diluted in 190µl DEPC treated water) was added to 700 µl of prepared lysis solution.
133 Samples were then inactivated for 10 minutes at room temperature within the safety cabinet before
134 automated RNA extraction using a Kingfisher Flex (Thermofisher). RNA was eluted in 90 µl of NFW.

135 *Roche FLOW system*

136 RNA extraction was carried out on a MagNA Pure 96 (MP96) extraction robot using the MagNA Pure
137 96 DNA and Viral Nucleic Acid Small Volume kit (Roche) and the Pathogen 200 universal protocol
138 v4.0.

139 *Qiagen QIAsymphony*

140 RNA extraction was carried out using the QIASymphony Virus/Bacteria Mini Kit (Qiagen) by the
141 CellFree200 Default IC protocol with a 60 µl extract elution volume.

142

143 **SARS-CoV-2 Real-Time RT-qPCR**

144 RNA was analysed using a range of different methods available at each site:

145 *CerTest VIASURE SARS-CoV-2 real time qPCR assay*

146 Single step RT-qPCR against the *ORF1ab* region and *N1* gene target of SARS-CoV-2 was carried out
147 using the CerTest VIASURE SARS-CoV-2 real time PCR kit (CerTest Biotech SL, Zaragoza, Spain)
148 according to manufacturer's instructions for use (IFU) on either the ThermoFisher QuantStudio 5 or

149 BioMolecular Systems MIC instruments, using 5 µl of extracted RNA per reaction. RNA extracted
150 using the Maxwell® RSC Viral Total Nucleic Acid Purification Kit was analysed using this assay.

151 *COVID-19 genesig® Real-Time qPCR assay*

152 Single step RT-qPCR against the *ORF1ab* region of SARS-CoV-2 was carried out using the COVID-19
153 genesig® Real-Time PCR assay real time PCR assay (Primerdesign Ltd, Chandler's Ford, UK) according
154 to manufacturer's instructions for use (IFU) on BioMolecular Systems MIC instruments, using 5 µl of
155 extracted RNA per reaction. RNA extracted using the Maxwell® RSC Viral Total Nucleic Acid
156 Purification Kit was analysed using this assay.

157 *Corman et al. Real-Time qPCR assay*

158 Single step RT-qPCR against the *E* gene target of SARS-CoV-2 was carried out with the Corman *et al.*
159 (3) primers using the AgPath-ID™ PCR kit (Thermofisher) according to manufacturer's instructions for
160 use (IFU) on an Aria qPCR Cycler (Agilent) and results analysed using the Agilent AriaMX 1.5
161 software, using 5 µl of extracted RNA per reaction. RNA extracted using the MagMAX™CORE Nucleic
162 acid purification kit were analysed using this assay.

163 RT-qPCR was carried out on an Applied Biosystems Fast 7500 PCR thermocycler in standard run
164 mode using the SARS-CoV-2 *E* gene Sarbeco assay using MS2 as an internal extraction control and
165 aliquots of SARS-CoV-2/England/2/2020 as a positive control. The master mix comprised *E*- gene F
166 and R primers and TM-P (400 nM, 400 nM and 200 nM final concentration respectively), MS2
167 primers and TM probe (20 nM, 20 nM and 40 nM final concentration respectively), 4 x TaqMan® Fast
168 Virus 1-Step Master Mix made up with molecular-grade nuclease free water (Ambion) to a final
169 volume of 15 µl. 5 µl of AVE buffer extract was used at a template and added to the 15 µl mastermix.
170 Cycling conditions were 55°C for 10 min, followed by 94°C for 3 min and 45 cycles of 95°C for 15 s
171 and 58°C for 30 s.

172 *SARS-CoV-2 (2019-nCoV) CDC qPCR Probe Assay*

173 Single step RT-qPCR against the *N1* and *N2* gene targets of SARS-CoV-2 was carried out using
174 integrated design technologies kit (IDT; Catalogue number: 10006606) according to manufacturer's
175 instructions for use (IFU) on either a LC480 II or ABI 7500 FAST instrument. RNA extracted on Qiagen
176 QIAsymphony and the Roche FLOW system were analysed using this RT-qPCR assay.

177

178 **RT-LAMP**

179 RT-LAMP assays were performed using OptiGene Ltd. (Horsham, UK) COVID-19_RT-LAMP kits, as
180 described previously(4), with the following modifications. The COVID-19_RNA RT-LAMP KIT-500 kit
181 was used for RNA RT-LAMP and the COVID-19_Direct PLUS RT-LAMP KIT-500 was used for Direct RT-
182 LAMP directly on oropharyngeal/nasopharyngeal swabs or saliva samples. The COVID-19_Direct
183 PLUS RT-LAMP KIT-500 kit also includes a sample preparation buffer, RapiLyze. For RNA RT-LAMP 5
184 µl of extracted RNA was added to the reaction. For the Direct PLUS RT-LAMP, 50 µl sample (swab
185 VTM or neat saliva) was added to 50 µl RapiLyze, vortexed and placed in a dry heat block pre-heated
186 to 98°C for 2 mins. 5 µl of the treated sample was added to each reaction.

187 The anneal temperature (Ta) that confirmed a positive result for Direct RT-LAMP was modified to
188 81.5°C and 85.99°C because of the effect of RapiLyze buffer on the reaction.

189

190 **SARS-CoV-2 viral culture of clinical samples across a C_T range**

191 For culture 100 µl and 100 µl of a 1 in 10 dilution of the first 10 samples (with predicted lower C_T
192 values) and 100 µl from the second twenty samples (with higher predicted C_T values) were added to
193 a 25 cm^2 flasks containing 80% confluent Vero E6 cells and allowed to adsorb for 1 hour. Five ml of
194 Minimum Essential Medium (MEM) (Gibco) + HEPES (Gibco) + 4% foetal calf serum FCS (Sigma) + 1 x
195 antibiotic-antimycotic (Gibco) was added to each flask and incubated for 1 week at 37°C. Two
196 negative control flasks to which 100 µl MEM + 4% FCS was added in place of sample, were set up in

197 parallel. Cultures were checked visually for cytopathic effect (cpe). Where cpe was not observed
198 after 1 week, 500 µl of supernatant was passed into a fresh flask containing Vero E6 cells for a
199 further two passages. At the beginning and end of each passage 140 µl of supernatant was collected
200 for SARS-CoV-2 RT-qPCR as described before.

201 To determine the sensitivity of isolation method for SARS-CoV-2 from clinical samples, a virus stock
202 titred by plaque assay (HCM/V/53), a P3 working bank grown from SARS-CoV-2 Strain England 2,
203 from Public Health England, was diluted in MEM to give virus dilutions containing 1000 pfu to 0.01
204 pfu. Virus isolation was performed as above in duplicate. After 72 hours of incubation flasks were
205 checked for cpe, and for those where cpe was observed the supernatant was collected for RT-qPCR.
206 Any flasks not showing cpe after 7 days were passed on to fresh cells and resampled as described
207 above.

208

209 **Data analysis**

210 Overall diagnostic sensitivity and specificity (including 95% Clopper-Pearson confidence intervals)
211 were calculated by the aggregation of individual site data for each method (RNA and Direct RT-
212 LAMP) for each sample type (swabs and saliva). To demonstrate the effectiveness of detecting
213 samples with higher viral load, confusion matrices are quoted where the threshold for *positive*
214 sample inclusion varies, i.e., for $C_T \leq 25$, only positive samples with $C_T \leq 25$ are included.

215 To account for site heterogeneity, a bivariate meta-analysis model is additionally applied at the site
216 level to produce a summary sensitivity and specificity for each method and sample type(12). Within-
217 study variability for sensitivity $\rho_{se,i}$ and specificity $\rho_{se,i}$ are assumed to follow independent binomial
218 distributions

219 $$x_{se,i} \sim B\left(n_{se,i}, \rho_{se,i}\right), \qquad x_{sp,i} \sim B(n_{sp,i}, \rho_{sp,i})$$

220 where $x_{se,i}, x_{sp,i}$ represent the number testing positive for site i respectively, and $n_{se,i}, n_{sp,i}$

221 represent the number testing positive and negative by RT-qPCR for site i respectively. The between-

222 study heterogeneity is represented by a bivariate normal distribution for the logit-transformed

223 sensitivity $\mu_{se,i}$ and specificity $\mu_{sp,i}$

224 $$\begin{pmatrix} \mu_{se,i} \\ \mu_{sp,i} \end{pmatrix} \sim N\left(\begin{pmatrix} \mu_{se} \\ \mu_{sp} \end{pmatrix}, \begin{pmatrix} \sigma_{se}^2 & \sigma_{se,sp} \\ \sigma_{se,sp} & \sigma_{sp}^2 \end{pmatrix}\right)$$

225 where μ_{se}, μ_{sp} represent the expected logit sensitivity and specificity, σ_{se}^2,σ_{sp}^2 represent the

226 between-study variance in the logit sensitivity and specificity, and $\sigma_{se,sp}$ represents the covariance

227 between the logit sensitivity and specificity. For Direct RT-LAMP, we fit a univariate normal

228 distribution for the logit-transformed sensitivity only due to the absence of false positives across all

229 sites.

230 In addition, the sensitivity as a function of viral load was assessed for RNA RT-LAMP and Direct RT-

231 LAMP on both swab and saliva samples. This was performed through the conversion of each sample

232 C_T value to viral load in gene copies/ml for all sample sets. As the relationship between C_T value and

233 viral load varied according to the RT-qPCR method used; a dilution series was utilised for each

234 method to standardise these values for two of the four aforementioned RT-qPCR methods (CerTest

235 VIASURE SARS-CoV-2 real time PCR kit, and Corman *et al* RT-qPCR assay *E* gene), which was used for

236 testing 100% of the swab samples, 90% of the saliva samples used for Direct RT-LAMP, and 83% of

237 the saliva samples used for RNA RT-LAMP. The logarithm of the viral load was then fitted to the C_T

238 values for both methods using linear regression followed by converting the C_T values to viral load

239 based on which method had been used to evaluate the samples. For the remaining samples (n= 56)

240 that utilised one of the other two RT-qPCR methods for which viral load was not standardised

241 against a C_T value, the conversion derived from the CerTest VIASURE SARS-CoV-2 real time PCR kit

242 dilution series was applied, the assumption that the *N* gene C_T values are the most similar(13–15).

For the CerTest VIASURE SARS-CoV-2 real time PCR kit, the following relationship between log viral load and C_T value was applied:

$$\log_{10} V = (45.257 - C_T) / \ 3.523$$

and similarly, for the Corman *et al* RT-qPCR assay:

$$\log_{10} V = (45.806 - C_T) \ / \ 3.717$$

where V represents the viral load in copies/ml.

Viral load was grouped according to the following categories (in copies/ml): $<10^3$, 10^3-10^4, 10^4-10^5, 10^5-10^6, 10^6-10^7 and $>10^7$ then the diagnostic sensitivity was calculated according to viral load group with associated Clopper-Pearson 95% confidence intervals.

The site meta-analysis was produced using R 3.5.3. Confusion matrices, sensitivity, specificity, sensitivity as a function of viral load calculations, and the production of scatter graphs showing the relationship between RT-LAMP results and C_T were performed using Python 3.8.6.

257 **Results**

258 **RNA RT-LAMP**

259 VTM from 12,619 naso/oropharyngeal swabs were assayed. 265 swab samples were from known
260 symptomatic individuals and 2073 swab samples were from known asymptomatic individuals. The
261 clinical status of the remaining samples (n= 10,281) was unknown.

262 12,521 neat saliva samples were assayed, none of which were from known symptomatic individuals.
263 12,365 of these samples were from known asymptomatic individuals. The clinical status of the
264 remaining saliva samples (n= 156) was unknown.

265 **Direct RT-LAMP**

266 VTM from 559 naso/oropharyngeal swabs were assayed. 170 swab samples were from known
267 symptomatic individuals and 310 samples were from known asymptomatic individuals and the
268 clinical status of the remaining swab samples (n= 79) was unknown.

269 86,760 neat saliva samples were assayed. 93 samples were from known symptomatic individuals and
270 86,593 samples were from known asymptomatic individuals. The clinical status of the remaining
271 samples (n= 74) was unknown. In addition, 10 separate longitudinal daily saliva samples were
272 provided from one individual as a time course from development of symptoms to three days post
273 resolution of symptoms.

274

275 **RNA RT-LAMP on naso/oropharyngeal swabs**

276 A total of 12,619 swab samples were assayed by RNA RT-LAMP, of which 254 were RT-qPCR positive
277 and 12,365 were RT-qPCR negative. RNA RT-LAMP detected 244 of the 254 positives (Figure 1a and
278 Table 1). Only one of the 12,365 samples negative by RT-qPCR was positive by RNA RT-LAMP. 588
279 samples were tested in duplicate and 12,031 were tested as single replicates. Of those samples

280 tested in duplicate seven were detected by RNA RT-LAMP in only a single replicate (C_Ts 27.00, 32.66,
281 33.14, 33.16, 34.07, 35.05, and 37.20 all of these had received at least one freeze thaw before
282 analysis. Overall diagnostic sensitivity (DSe) was 96.06% (95% CI 92.88-98.12) and specificity (DSp)
283 99.99% (95% CI 99.95-100.00), which is corrected to DSe 95.98% (95% CI 92.70-97.83) and DSp
284 99.99% (95% CI 99.94-100.00) after site meta-analysis Diagnostic sensitivity of samples with a $C_T \leq 25$
285 (n= 123) was 100.00% (95% CI 96.76-100.00) and specificity 99.99% (95% CI 99.95-100.00), and of
286 samples with a $C_T \leq 33$ (n=180) was 98.65% (95% CI 96.10-99.72) and specificity 99.99% (95% CI
287 99.95-100.00).

288 **Table 1.** Diagnostic sensitivity and specificity of RNA RT-LAMP on swabs compared with RT-qPCR

		RT-qPCR Pos	RT-qPCR Neg	Total		%	**95% CI**
C_T <45 Swab	RNA RT-LAMP Pos	244[†]	1	245	**DSe**	96.06	92.88-98.12
	RNA RT-LAMP Neg	10	12364	12374	**DSp**	99.99	99.95-100
	Total	254	12365				
		RT-qPCR Pos	RT-qPCR Neg	Total		%	**95% CI**
C_T <33 Swab	RNA RT-LAMP Pos	219	1	220	**DSe**	98.95	96.10-99.72
	RNA RT-LAMP Neg	3	12364	12367	**DSp**	99.9	99.95-100
	Total	222	12365				
		RT-qPCR Pos	RT-qPCR Neg	Total		%	**95% CI**
C_T <25 Swab	RNA RT-LAMP Pos	112	1	113	**DSe**	100	96.76-100
	RNA RT-LAMP Neg	0	12364	12364	**DSp**	99.9	99.95-100
	Total	112	12365				

289 [†]Five samples included in this number were positive by RT-qPCR but did not have an associated C_T value due to being
290 assayed on a platform that did not produce a C_T value. DSe: Diagnostic sensitivity. DSp: Diagnostic specificity

291

292

293 **Direct RT-LAMP on naso/oropharyngeal swabs**

294 559 swab samples were assayed by Direct RT-LAMP of which 199 were RT-qPCR positive and 360
295 were RT-qPCR negative. Direct RT-LAMP detected 140 of the 199 samples positive by RT-qPCR
296 (Figure 1b and Table 2). 195 samples were tested in duplicate and 364 tested as single replicates.
297 Seven of 195 samples tested in duplicate were positive by Direct RT-LAMP in only one replicate (C_T
298 27.51, 27.95, 28.15, 28.15, 28.87, 28.92, and 28.95) all these samples had received at least one
299 freeze thaw before analysis. Overall diagnostic sensitivity was 70.35% (95% CI 63.48-76.60) and
300 specificity 100% (95% CI 98.98-100). After correction by site meta-analysis, the DSe is corrected to
301 67.59% (95% CI 53.71-78.94). Diagnostic sensitivity of samples with a $C_T \leq 25$ (n= 113) was 100% (95%
302 CI96.34-100) and specificity 100% (95% CI 98.98-100), and of samples with a $C_T \leq 33$ (n= 182) was
303 77.78% (95% CI 70.99-83.62) and specificity 100% (95% CI 98.98-100).

304

305 **Table 2.** Diagnostic sensitivity and specificity of Direct RT-LAMP on swabs compared to RT-qPCR

		RT-qPCR Pos	RT-qPCR Neg	Total		%	**95% CI**
C_T <45 Swab	Direct RT-LAMP Pos	140	0	140	**DSe**	70.35	63.48-76.60
	Direct RT-LAMP Neg	59	360	419	**DSp**	100	98.98-100
	Total	199	360				
		RT-qPCR Pos	RT-qPCR Neg	Total		%	**95% CI**
C_T <33 Swab	Direct RT-LAMP Pos	140	0	140	**DSe**	77.78	70.99-83.62
	Direct RT-LAMP Neg	40	360	400	**DSp**	100	98.98-100
	Total	180	360				
		RT-qPCR Pos	RT-qPCR Neg	Total		%	**95% CI**
C_T <25 Swab	Direct RT-LAMP Pos	99	0	99	**DSe**	100	96.34-100
	Direct RT-LAMP Neg	0	360	360	**DSp**	100	98.98-100
	Total	99	360				

306 DSe: Diagnostic sensitivity. DSp: Diagnostic specificity

307

308

309 **RNA RT-LAMP on saliva**

310 Saliva samples numbering 12,521 were assayed by RNA RT-LAMP of which 155 were RT-qPCR
311 positive and 12,366 were RT-qPCR negative. RNA RT-LAMP detected 133 of the 155 samples that
312 were positive by RT-qPCR (Figure 1c and Table 3). Only one of the 12,366 samples negative by RT-
313 qPCR was positive by RNA RT-LAMP. 44 samples were tested in duplicate and 12,477 were tested as
314 single replicates. All samples tested in duplicate were positive in both replicates. Overall diagnostic
315 sensitivity was 80.65% (95% CI 73.54-86.54) and specificity 99.99% (95% CI 99.95-100), which is
316 corrected to DSe 79.05% (95% CI 68.87 – 86.55) and DSp 99.99% (95% CI 99.74-100) after site meta-
317 analysis. Diagnostic sensitivity of samples with a $C_T \leq 25$ (n= 74) was 100% (95% CI 93.73-100) and
318 specificity 99.99% (95% CI 99.95-100), and of samples with a $C_T \leq 33$ (n= 150) was 87.32% (95% CI
319 80.71-92.31) and specificity 99.95 (95% CI 99.95-100.00).

320

321

322 **Table 3.** Diagnostic sensitivity and specificity of RNA RT-LAMP on saliva compared to RT-qPCR

		RT-qPCR Pos	RT-qPCR Neg	Total		%	95% CI
C_T <45 Saliva	RNA RT-LAMP Pos	125	1	126	**DSe**	80.65	73.54-86.54
	RNA RT-LAMP Neg	30	12365	12395	**DSp**	99.99	99.95-100
	Total	155	12366				
		RT-qPCR Pos	RT-qPCR Neg	Total		%	95% CI
C_T <33 Saliva	RNA RT-LAMP Pos	124	1	125	**DSe**	87.32	80.71-92.31
	RNA RT-LAMP Neg	18	12365	12383	**DSp**	99.99	99.95-100
	Total	142	12366				
		RT-qPCR Pos	RT-qPCR Neg	Total		%	95% CI
C_T <25 Saliva	RNA RT-LAMP Pos	57	1	58	**DSe**	100	93.73-100
	RNA RT-LAMP Neg	0	12365	12365	**DSp**	99.99	99.95-100
	Total	57	12366				

323 DSe: Diagnostic sensitivity. DSp: Diagnostic specificity

324

325

326 **Direct RT-LAMP on saliva**

327 86,760 saliva samples were tested by Direct RT-LAMP of which 247 were RT-qPCR positive and 7,195
328 were RT-qPCR negative (79,318 were negative on RT-LAMP but were not tested by RT-qPCR) (Figure
329 4d and Table 4). Direct RT-LAMP detected 209 of the 247 samples positive by RT-qPCR. 83 samples
330 were tested in duplicate and 86,677 were tested as single replicates. Nine of the 83 samples tested
331 in duplicate were negative in one of the duplicates and all these samples had received at least one
332 freeze thaw before analysis (C_T 20.27, 21.28, 22.01, 24.42, 25.85, 27.35, 28.52, and 30.37). Overall
333 diagnostic sensitivity was 84.62% (95% CI 79.50-88.88) and specificity 100% (95% CI 99.72-100).
334 After correction by site meta-analysis, DSe is corrected to 84.24% (95% CI 55.03-95.89). Diagnostic
335 specificity was calculated using only the confirmed RT-qPCR negative samples. Diagnostic sensitivity
336 of samples with a $C_T \leq 25$ (n= 126) was 99.01% (95% CI 94.61-99.97) and specificity 100.00% (95% CI
337 99.72-100), and of samples with a $C_T \leq 33$ (n= 237) was 87.61% (95% CI 82.69-91.54) and specificity
338 100% (95% CI 99.72-100).

339 **Table 4.** Diagnostic sensitivity and specificity of Direct RT-LAMP on saliva compared to RT-qPCR.

		RT-qPCR Pos	RT-qPCR Neg	Total		%	95% CI
C_T<45 Saliva	Direct RT-LAMP Pos	209	0	209	**DSe**	84.62	79.50-88.88
	Direct RT-LAMP Neg	38	7195*	7233	**DSp**	100.00	99.95-100.00
	Total	247	7195				
		RT-qPCR Pos	RT-qPCR Neg	Total		%	95% CI
C_T <33 Saliva	Direct RT-LAMP Pos	205	0	205	**DSe**	87.61	82.69-91.54
	Direct RT-LAMP Neg	29	7195*	7224	**DSp**	100.0	99.95-100.00
	Total	234	7195				
		RT-qPCR Pos	RT-qPCR Neg	Total		%	95% CI
C_T <25 Saliva	Direct RT-LAMP Pos	100	0	100	**DSe**	99.01	94.61-99.97
	Direct RT-LAMP Neg	1	7195*	7196	**DSp**	100.0	99.95-100.00
	Total	101	7195				

340 *85,177 samples were negative on RT-LAMP but only 7,196 were confirmed negative by RT-qPCR. Only those
341 which were confirmed negative by RT-qPCR were included in the calculations.

342

343 **Relationship between cycle threshold (C_T) value and time to positivity (Tp)**

344



345

346

347 **Figure 1a-d:** RT-LAMP on swabs (a: RNA RT-LAMP; b: Direct RT-LAMP) and saliva (c: RNA RT-LAMP; d: Direct

348 RT-LAMP). Time to positivity [Tp] in minutes plotted against RT-qPCR Cycle Threshold [C_T]. Samples which were

349 negative by RT-qPCR are not shown. Samples which were negative by RT-LAMP are shown with 0 time to

350 positivity. Results of linear ordinary least squared regression are shown for samples which were RT-LAMP

351 positive with corresponding 95% confidence interval.

352

353 The relationship between C_T value and Tp was explored with the results shown in Figure 1. Whilst
354 there is a weak linear relationship between C_T value and Tp across all methods and sample types, a
355 stronger linear relationship was observed in swab samples with $R^2 = 0.431$ for RNA RT-LAMP and
356 $R^2 = 0.462$ for Direct RT-LAMP. There was a notably weaker linear relationship in saliva samples
357 $R^2 = 0.201$ for RNA RT-LAMP and $R^2 = 0.204$ for Direct RT-LAMP. For RNA RT-LAMP, there was a
358 notable increase in Tp variance, σ_{Tp}^2, after C_T =20 across both sample types. On saliva samples,
359 $\sigma_{Tp}^2 = 0.81$ for $C_T \leq 20$, and $\sigma_{Tp}^2 = 20.41$ for $C_T > 20$; on swabs samples, $\sigma_{Tp}^2 = 1.96$ and $C_T \leq 20$, and
360 $\sigma_{Tp}^2 = 15.72$ for $C_T > 20$

361

362 **Individual time course**

363 In the time course experiment SARS-CoV-2 RNA was detected from day 5 (at the onset of symptoms)
364 up to day 12 post suspected initial exposure using Direct RT-LAMP and up to day 13 by RNA RT-
365 LAMP, encompassing the full six days where symptoms were recorded (Supplementary Information).

366

367 **SARS-CoV-2 viral culture of clinical samples across a C_T range**

368 Although not a large sample size; a negative result via Direct RT-LAMP does seem indicate the
369 presence of culturable virus is less probable and recoverable virus $C_T > 25$ for RDRP/ORF1ab target is
370 less likely. The sensitivity of the viral culture assay is presented in Supplementary data 2 of 1 pfu/ml.

371

372

373

374

375

Sample	Direct RT-LAMP	RNA RT-LAMP	C_T values			cpe	Decrease in C_T from P0 D0 to P0 D7	C_T decrease D0 to D7	
			Genesig RDRP gene	VIASURE ORF1ab	SARS-CoV E gene Sarbeco assay			P1	P2
1	POS	POS	19.9	18.7	17.8	+ P2¶	+	n/a	n/a
2	POS	POS	21.3	19.9	19.0	+	+	n/a	n/a
3	POS	POS	21.6	19.1	18.5	+	+	n/a	n/a
4	POS	POS	22.6	20.8	19.8	+	+	n/a	n/a
5	POS	POS	22.9	21.6	21.0	+	+	n/a	n/a
6	POS	POS	23.7	20.6	20.6	+	+	n/a	n/a
7	NEG*	POS	24.3	21.4	20.4	+	+	n/a	n/a
8	NEG*	POS	25.3	22.0	21.3	No cpe	n/a	n/a	n/a
9	NEG*	POS	26.0	23.7	23.0	+	+	n/a	n/a
10	NEG*	NEG	36.1	31.5	32.7	No cpe	n/a	n/a	n/a
11	NEG	POS	-			No cpe	No	No	No
12	NEG	POS	39.2			No cpe	No	No	No
13	NEG	POS	35.2			No cpe	No	No	No
14	NEG	NEG	34.6			No cpe	No	No	No
15	NEG	POS	35.4			No cpe	No	No	No
16	NEG	POS	36.2			No cpe	No	No	No
17	POS	POS	35.8			No cpe	No	No	No
18	POS	POS	34.5			No cpe	No	No	No
19	NEG	POS	35.1			No cpe	No	No	No
20	POS	POS	30.0			No cpe	No	No	No
21	POS	POS	32.3			No cpe	No	No	No
22	NEG	POS	34.6			No cpe	No	No	No
23	POS	POS	31.3			No cpe	No	No	No
24	NEG	POS	30.3			No cpe	No	No	No
25	NEG	POS	30.0			No cpe	No	No	No
26	NEG	POS	31.5			No cpe	No	No	No
27	NEG	POS	30.7			+	No	No	No
28	POS	POS	29.9			No cpe	No	No	No
29	POS	POS	29.4			No cpe	No	No	No
30	NEG*2	POS	28.2			+	Yes	No	No

Table 5: Viral culture of positive VTM from oro/pharyngeal swabs and assay results. Original sample result was generated from Genesig RDRP assay at time of diagnosis. *Previously un-optimised method without lysis buffer. *2 – precipitate observed in lysis mix.

381 **Performance of RT-LAMP across viral load groups**



382

383



384

385 **Figure 2**: Performance of the RNA RT-LAMP and Direct RT-LAMP assays on both saliva and swab samples
386 according to viral load groupings.

387 The sensitivity of the RNA and Direct RT-LAMP assays across viral load groups is shown in Figure 2.
388 For RNA RT-LAMP, samples which were positive by RT-qPCR containing >10^5 copies/ml were
389 consistently identified as positive with no samples returning a negative result. Below this copy
390 number, sensitivity is reduced for both saliva and swab samples, reaching ~60% in swab samples
391 exclusively with viral loads <10^3 copies/ml, and an approximately linear drop in sensitivity from 100%
392 to 0% between viral loads of 10^5 and 10^3 copies/ml respectively in saliva samples. For Direct RT-
393 LAMP, all but one saliva sample were detected above 10^6 copies/ml. On swab samples, sensitivity is
394 reduced on samples containing below <10^5 copies/ml, dropping from 85% at viral loads of 10^5–10^6
395 copies/ml, to 30% in the 10^4–10^5range. On saliva samples, sensitivity is reduced in the 10^4–10^5 range
396 to a sensitivity of 80% but then reduces further within the 10^3–10^4 range, to 30%.

397

398

399

400

401

402

403

404

405

406

407

408

409 **Site meta-analysis**



410

Direct RT-LAMP Swabs

Site	TP	FP	FN	TN	Sensitivity (95% CI)	Specificity (95% CI)
Site A	7	0	12	0	0.37 [0.16, 0.62]	Not estimatable
Site B	63	0	19	349	0.77 [0.66, 0.85]	1.00 [0.99, 1.00]
Site C	39	0	17	0	0.70 [0.56, 0.81]	Not estimatable
Site D	31	0	11	11	0.74 [0.58, 0.86]	1.00 [0.72, 1.00]
Overall	140	0	59	360	0.70 [0.63, 0.77]	1.00 [0.99, 1.00]
Random effects model					0.68 [0.54, 0.79]	1.00 [0.99, 1.00]



RNA RT-LAMP Saliva

Site	TP	FP	FN	TN	Sensitivity (95% CI)	Specificity (95% CI)
Site A	78	1	14	3154	0.85 [0.76, 0.91]	1.00 [1.00, 1.00]
Site B	1	0	0	3645	1.00 [0.03, 1.00]	1.00 [1.00, 1.00]
Site C	18	0	9	2371	0.67 [0.46, 0.83]	1.00 [1.00, 1.00]
Site D	28	0	7	3195	0.80 [0.63, 0.92]	1.00 [1.00, 1.00]
Overall	125	1	30	12365	0.81 [0.74, 0.87]	1.00 [1.00, 1.00]
Random effects model					0.79 [0.69, 0.87]	1.00 [1.00, 1.00]



Direct RT-LAMP Saliva

Site	TP	FP	FN	TN	Sensitivity (95% CI)	Specificity (95% CI)
Site A	144	0	12	5867	0.92 [0.87, 0.96]	1.00 [1.00, 1.00]
Site B	42	0	18	527	0.70 [0.57, 0.81]	1.00 [0.99, 1.00]
Site C	16	0	0	52	1.00 [0.79, 1.00]	1.00 [0.93, 1.00]
Site D	7	0	8	749	0.47 [0.21, 0.73]	1.00 [1.00, 1.00]
Overall	209	0	38	7195	0.85 [0.80, 0.89]	1.00 [1.00, 1.00]
Random effects model					0.84 [0.55, 0.96]	1.00 [1.00, 1.00]



414

415 **Figure 3**: Forest plots for each method and sample type showing site heterogeneity in sensitivity and specificity,
416 with overall estimates and the resulting expected sensitivity and specificity retrieved from each respective
417 bivariate random effects model.

418

419 Site-level confusion matrices, sensitivity, and specificity per method and sample type in Figure 3.
420 Heterogeneity between sites for the specificity was minimal for all combinations of method and
421 sample type, with the random effects model matching the overall aggregated sample calculation. For
422 sensitivity, heterogeneity was minimal between sites for RNA RT-LAMP. However, for Direct RT-
423 LAMP, sensitivity showed significant overall heterogeneity (bivariate model variance: $\sigma_{se}^2 = 1.817$
424 on saliva samples; $\sigma_{se}^2 = 0.228$ on swab samples). Between-site variations in the viral load of the
425 samples tested contributed a minority of the heterogeneity, but sensitivity was consistently high in
426 samples with higher viral loads (i.e., >10^6 copies/ml, as shown in Figure 2), while being more
427 heterogeneous between sites in samples with lower viral loads. Sensitivity at lower viral loads was
428 highest in the sites with the most established testing programmes.

429

430 **Discussion**

431 Testing of human populations for SARS-CoV-2 nucleic acid has been hampered by both logistical
432 (e.g., swab availability) and physical (e.g., discomfort from repeat swab testing) constraints. The aim
433 of this study was to evaluate an optimised sample preparation method, building upon previously
434 published methods for the extraction-free detection of SARS-CoV-2 by RT-LAMP primarily from
435 saliva(4,11). Collection of saliva is non-invasive and does not require a trained individual or specialist
436 consumables for collection of a quality sample. Utilising a non-invasive sampling method should
437 open testing to more individuals who dislike or are unable to tolerate having a
438 nasopharyngeal/oropharyngeal swab taken. The salivary glands are reported to be early targets of
439 SARS-CoV-2 infection(16),(17), and studies have demonstrated the detection of high viral loads of
440 SARS-CoV-2 from saliva, similar to those observed from nasopharyngeal/oropharyngeal
441 swabs(5,7,18),(19). Additionally, several studies have demonstrated that SARS-CoV-2 viral RNA could
442 be detected from saliva for a similar duration post onset of clinical signs when compared to
443 combined naso/oropharyngeal swabs(20–22), highlighting saliva as a valuable tool for SARS-CoV-2
444 detection.

445 Direct detection negates the requirement for RNA extraction(23),(24), for which there has previously
446 been competition for reagents and often requires expensive extraction equipment including liquid
447 handling automation. This extraction-free method decreases turnaround time from sample
448 collection to result. The Direct RT-LAMP method is straight forward and rapid, allowing the test to be
449 performed in a wide range of settings, including near-patient hospital laboratories and pop-up or
450 mobile laboratories. However, previously evaluated extraction-free sample preparation methods
451 using RT-LAMP from saliva samples have demonstrated reduced sensitivity(4,11), likely due to the
452 inhibitory factors found within saliva that may affect molecular tests such as RT-LAMP and RT-
453 qPCR(25,26). The simple sample preparation method evaluated in the study aimed to improve upon
454 these methods by utilising the addition of a novel proprietary reagent, RapiLyze©, designed to

455 neutralize common sample inhibitors. A subsequent heat step of 98°C for two minutes prior to
456 addition to the RT-LAMP master mix renders SARS-CoV-2 inactive as confirmed by infectivity analysis
457 using live virus inactivation studies (See supplementary 2). Downstream steps are then able to
458 proceed outside of traditional containment level laboratory settings broadening its clinical utility.

459 Our study utilised high numbers of combined naso/oropharyngeal swabs (n= 559) and saliva samples
460 (n = 86,760) for the evaluation of this novel sample preparation method in combination with the
461 Direct RT-LAMP assay. RNA RT-LAMP was also performed on >25,000 samples for comparison,
462 providing updated values for the performance of the assay reported previuosly(4,11,27). Correlation
463 between C_T value and sample viral copy number has been demonstrated within this and other
464 studies, with lower C_T values C_T (< 25 and < 33) indicating a higher probability that the sample
465 contains recoverable active virus, and consequently the likelihood that the individual may be
466 infectious to others[4,25,](28–31). As a result, the RNA and Direct RT-LAMP assays were compared with
467 RT-qPCR results in groups with three different C_T cut-off values: <45, <33 and <25. This was
468 completed so that the performance of the assays in different clinical scenarios (use case) could be
469 determined: (i) C_T<45: does the RT-LAMP assay (either RNA or Direct) compare with RT-qPCR for all
470 reportable C_T values?; (ii) C_T<33: can the RT-LAMP assay detect those individuals that have a
471 medium-high levels of viral RNA in their specimens, with an ORF1ab target being analogous with
472 viral copy number because it is exclusively a genomic target(14); and (iii) C_T<25: can the RT-LAMP
473 assay detect those individuals that have a high level of viral RNA in their specimens?

474 In our study, diagnostic sensitivity for RNA RT-LAMP on swab and saliva samples was improved when
475 compared to a previous report utilising this method (Fowler *et al*., 2020), with values of >96% and
476 >80%, respectively when considering all C_T values, and 100% for both sample types when considering
477 C_T<25 with these samples having a high probability of containing replicating virus for over 24,000
478 samples tested. Direct RT-LAMP sensitivity on swab samples was also improved from the previous
479 method with 100% sensitivity for C_T<25, 77.78% for C_T<33 and 70.35% for C_T<45 across 559 samples

480 used for this evaluation. In contrast, sensitivity for Direct RT-LAMP on saliva was in general higher
481 than that determined for swabs (C_T<33 = 87.61%, C_T<45 = 84.62%), apart from the group with C_T
482 values below <25, which had a reported sensitivity of 99.01%. These results support previous reports
483 which demonstrate comparable performance when comparing paired swabs and saliva
484 samples(32,33), and that one sample type is not superior to the other. Interestingly, the diagnostic
485 sensitivity for RNA and Direct RT-LAMP for saliva samples was almost equivalent (80.65% and
486 84.62%, respectively) suggesting that RNA extraction may not even be required when performing
487 testing on saliva samples.

488 Previous studies have described the importance of identifying asymptomatic individuals, particularly
489 those with high viral loads(34–37). The ability of the Direct RT-LAMP assay to reliably detect
490 individuals with medium-high viral loads in a simple to collect, non-invasive sampling process
491 highlights the suitability of this assay for both symptomatic and asymptomatic population screening.
492 This is particularly important in healthcare and care home staff where the use of asymptomatic
493 COVID-19 screening would reduce the risk of onward transmission of SARS-CoV-2, consequently
494 maintaining NHS capacity and Social Care capacity and more importantly, reducing the risk to
495 vulnerable individuals present within those environments(27).

496 It is important to note that when designing surveillance strategies for asymptomatic infection testing
497 as an intervention to reduce transmission, frequency of testing and result turnaround time may be
498 considered more significant than diagnostic sensitivity(38). 'Gold standard' tests with high sensitivity
499 such as RT-qPCR generally need to be performed in centralised testing facilities, often resulting in
500 increased reporting times, leading to a less effective control of viral transmission(38). In contrast,
501 point of care tests such as Lateral flow tests (LFT)(39) or those requiring only a basic/mobile
502 laboratory set-up such as Direct RT-LAMP, which have the ability to produce rapid results, can be
503 performed frequently e.g., daily or multiple times per week. Consequently, the likelihood of
504 sampling an individual when their viral load is highest as seen in the early, often pre-symptomatic

505 stages of infection increases, maximising the probability of rapidly detecting infectious cases,
506 allowing prompt isolation. In this use case sampling and testing frequency using a rapid assay with
507 suitable accuracy in detection of medium-high viral loads, but not necessarily optimal sensitivity over
508 the whole range including low to very low viral loads, is desirable or necessary(38,40). Frequent on-
509 site testing of asymptomatic NHS healthcare workers using Direct RT-LAMP has been successfully
510 implemented in the pilot study described here; and continues to be utilised. Direct-RT-LAMP has also
511 been used in a mass community based pilot in school and higher education settings(27), to identify
512 those individuals who may have been missed when surveillance relies only on symptomatic
513 individuals coming forward for testing. With the use of mobile or pop-up laboratories, Direct RT-
514 LAMP could also be used for risk-based mass testing, for example, targeting specific geographical
515 areas or vulnerable groups. The potential also exists for lyophilisation of the Direct RT-LAMP
516 reagents reported in other studies(41,42), which would minimise the necessity for trained personnel
517 by reducing pipetting steps and the requirement for a cold chain, allowing greater capacity of the
518 assay in multi-use case scenarios including point-of-care and in low- and middle-income countries
519 (LMICs).

520 Several experiments typical of a diagnostic performance evaluation were not performed as part of
521 this study, as they had been performed and reported previously. This included both analytical
522 specificity, which when tested against a panel of respiratory pathogens causing indistinguishable
523 clinical signs to COVID-19, demonstrated a high level of analytical specificity (100% in this case)(4)
524 and analytical sensitivity of the Direct RT-LAMP, which is reported to detect 1000 cp/ml(4,27,32).
525 Additionally, the RNA and Direct RT-LAMP assays evaluated as part of this study have been shown to
526 reliably detect the emerging variants of concern (VOC) including the B.1.1.7 alpha variant, the
527 501Y.V2 beta variant, the P1 gamma variant and the new rapidly spreading B.1.617.2 delta
528 variant(43–45). The emergence of further VOC could lead to a criticism of the RT-LAMP assay due its
529 reliance on a single target, ORF1ab, where mutations in the target region in a sample could lead to
530 false negatives. For RT-qPCR this has been observed during the current pandemic (46–48) where at

531 least a dual target assay is recommended(49). However, this is less likely to occur for the RT-LAMP
532 assay used in this pilot evaluation. Firstly, due to the multiple sets of primer pairs utilised, 3 pairs
533 with two pairs within the target region. This builds in redundancy to mutation not unlike a duplex
534 RT-qPCR. Secondly, the ORF1ab region is highly conserved and crucial for viral replication and fitness
535 in SARS-CoV-2. As a result, these regions are well maintained using a proofreading system via the
536 nsp14 protein(50) resulting in a more stable genome compared to many other RNA viruses.

537 The authors highlight the importance of incorporating an inhibition control into the next iteration of
538 the RT-LAMP assays. Although, the paired RT-LAMP and RT-qPCR data from this study show a good
539 correlation and any false negative results were likely due to the analytical sensitivity of the RT-LAMP
540 assay, not sample driven inhibition. To this end, a control primer set by OptiGene Ltd was evaluated
541 (PS-0010), targeting the human ribosomal protein LO gene. Preliminary analysis of the inhibition
542 control primers showed consistent detection across 279 saliva and 381 combined
543 naso/oropharyngeal swab samples using both RNA and Direct RT-LAMP (Supplement 1).
544 Incorporation of this inhibition control into the RT-LAMP assays would alleviate a potential limitation
545 of the current assays and further support quality assurance for use within a clinical diagnostic
546 setting.

547 This study demonstrated high sensitivity and specificity for a novel sample preparation method used
548 for SARS-CoV-2 Direct RT-LAMP, particularly in samples from which the individual would likely be
549 considered infectious, highlighting the usefulness of saliva as a simple to collect, non-invasive sample
550 type. The highly sensitive RNA RT-LAMP assay provides a rapid alternative with a reliance on
551 differing reagents and equipment to RT-qPCR testing, thus providing additional diagnostic capacity
552 and redundancy through diversity. Direct RT-LAMP may complement existing surveillance tools for
553 SARS-CoV-2 testing including other point-of-care and laboratory-based diagnostics and is applicable
554 to a variety of clinical scenarios, such as frequent, interval-based testing of asymptomatic individuals
555 that may be missed when reliance is on symptomatic testing alone. However, care should be taken

when considering frequency of testing, messaging around the role and interpretation of asymptomatic rapid tests, integration of data storage and access, and the challenges faced when scaling up surveillance to large populations.

The role out of a new testing strategy can often throw up interesting and unexpected experiences. These collective experiences and lessons learnt from setting up an NHS asymptomatic staff testing programme using Direct RT-LAMP will be shared in a future publication.

Funding

This work was partially funded by a Department of Health and Social Care award to the University of Southampton (Grant Reference Number 2020/032 (Feasibility study for city-wide testing using saliva 315 based LAMP testing)). The views expressed are those of the authors and not necessarily those of the Department of Health and Social Care. KMG is supported by the UK Medical Research Council 317 (MC_UU_12011/4), the National Institute for Health Research (NIHR Senior Investigator (NF-SI-0515- 318 10042) and NIHR Southampton Biomedical Research Centre (IS-BRC-1215-20004)) and the British 319 Heart Foundation (RG/15/17/3174). For part of this project, Emma Howson was on secondment at GeneSys Biotech Ltd., which was part funded by The Pirbright Institute Flexible Talent Mobility Account (FTMA) under BBSRC grant BB/S507945/1. ADB is currently supported by a Cancer Research UK Advanced Clinician Scientist award (C31641/A23923) and his laboratory is supported by CRUK Centre Birmingham (C17422/A25154) and the Birmingham Experimental Cancer Medicine Centre (C11497/A25127). Veronica Fowler, Stephen Kidd, Bryony Armson and Zandra Deans were on secondment to the Department of Health and Social Care for a period during this study. APHA laboratory activities and expertise was supported by both the Safe and Certain project APHACSKL0085 and Defra project APHANSOM0416.

580 **References**

581 1. Zhang J jin, Dong X, Cao Y yuan, Yuan Y dong, Yang Y bin, Yan Y qin, et al. Clinical
582 characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy Eur J
583 Allergy Clin Immunol. 2020;75(7):1730–41.

584 2. Johns Hopkins Coronavirus Resource Centre [Internet]. [cited 2021 Apr 19]. Available from:
585 https://coronavirus.jhu.edu/

586 3. Corman VM, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu DKW, et al. Detection of 2019
587 novel coronavirus (2019-nCoV) by real-time RT-PCR. Eurosurveillance. 2020;25(3):23–30.

588 4. Fowler VL, Armson B, Gonzales JL, Wise EL, Howson ELA, Vincent-Mistiaen Z, et al. A highly
589 effective reverse-transcription loop-mediated isothermal amplification (RT-LAMP) assay for
590 the rapid detection of SARS-CoV-2 infection. J Infect [Internet]. 2020;82(1):117–25. Available
591 from: https://doi.org/10.1016/j.jinf.2020.10.039

592 5. Zhu J, Guo J, Xu Y, Chen X. Viral dynamics of SARS-CoV-2 in saliva from infected patients. J
593 Infect. 2020;81(3):e48–50.

594 6. Ott IM, Strine MS, Watkins AE, Boot M, Kalinich CC, Harden CA, et al. Simply saliva: stability of
595 SARS-CoV-2 detection negates the need for expensive collection devices. medRxiv : the
596 preprint server for health sciences. 2020.

597 7. Azzi L, Baj A, Alberio T, Lualdi M, Veronesi G, Carcano G, et al. Rapid Salivary Test suitable for
598 a mass screening program to detect SARS-CoV-2: A diagnostic accuracy study. J Clean Prod.
599 2020;81.

600 8. Wei S, Suryawanshi H, Djandji A, Kohl E, Morgan S, Hod EA, et al. Field-deployable, rapid
601 diagnostic testing of saliva for SARS-CoV-2 [Internet]. Vol. 11, Scientific reports. Columbia
602 University Irving Medical Center, New York, NY, USA.; 2021. p. 5448. Available from:
603 http://europepmc.org/abstract/MED/33750853

604 9. Sri Santosh T, Parmar R, Anand H, Srikanth K, Saritha M. A Review of Salivary Diagnostics and
605 Its Potential Implication in Detection of Covid-19. Cureus. 2020;12(4).

606 10. Beaumont A, Raillon L, Ader F, Chatenoud L, Hueso T. Evaluation of different sample
607 treatments options in a simple and safe procedure for the detection of SARS-COV-2 in saliva.
608 2020;(January).

609 11. Howson ELA, Kidd SP, Armson B, Goring A, Sawyer J, Cassar C, et al. Preliminary optimisation
610 of a simplified sample preparation method to permit direct detection of SARS-CoV-2 within
611 saliva samples using reverse-transcription loop-mediated isothermal amplification (RT-LAMP).
612 J Virol Methods. 2021;289.

613 12. Reitsma JB, Glas AS, Rutjes AWS, Scholten RJPM, Bossuyt PM, Zwinderman AH. Bivariate
614 analysis of sensitivity and specificity produces informative summary measures in diagnostic
615 reviews. J Clin Epidemiol. 2005 Oct;58(10):982–90.

616 13. Bhargava A. Dynamic aspects of ORF1ab and N RNA cycle threshold values among COVID-19
617 patients in China. Infect Genet Evol [Internet]. 2021;87:104657. Available from:
618 https://www.sciencedirect.com/science/article/pii/S1567134820304883

619 14. Alexandersen S, Chamings A, Bhatta TR. SARS-CoV-2 genomic and subgenomic RNAs in
620 diagnostic samples are not an indicator of active replication. Nat Commun [Internet].
621 2020;11(1):6059. Available from: https://doi.org/10.1038/s41467-020-19883-7

622 15. Xu T, Chen C, Zhu Z, Cui M, Chen C, Dai H, et al. Clinical features and dynamics of viral load in

623 imported and non-imported patients with COVID-19. Int J Infect Dis IJID Off Publ Int Soc
624 Infect Dis. 2020 May;94:68–71.

625 16. Liu L, Wei Q, Alvarez X, Wang H, Du Y, Zhu H, et al. Epithelial Cells Lining Salivary Gland Ducts
626 Are Early Target Cells of Severe Acute Respiratory Syndrome Coronavirus Infection in the
627 Upper Respiratory Tracts of Rhesus Macaques. J Virol. 2011;85(8):4025–30.

628 17. Huang N, Pérez P, Kato T, Mikami Y, Okuda K, Gilmore RC, et al. SARS-CoV-2 infection of the
629 oral cavity and saliva. Nat Med. 2021 Mar;

630 18. To KKW, Tsang OTY, Leung WS, Tam AR, Wu TC, Lung DC, et al. Temporal profiles of viral load
631 in posterior oropharyngeal saliva samples and serum antibody responses during infection by
632 SARS-CoV-2: an observational cohort study. Lancet Infect Dis. 2020;20(5):565–74.

633 19. Tan SH, Allicock O, Armstrong-Hough M, Wyllie AL. Saliva as a gold-standard sample for SARS-
634 CoV-2 detection. Lancet Respir Med [Internet]. 2021;2600(21):19–21. Available from:
635 http://www.ncbi.nlm.nih.gov/pubmed/33887248

636 20. Uwamino Y, Nagata M, Aoki W, Fujimori Y, Nakagawa T, Yokota H, et al. Accuracy and stability
637 of saliva as a sample for reverse transcription PCR detection of SARS-CoV-2. J Clin Pathol.
638 2021;74(1):67–8.

639 21. Wyllie AL, Fournier J, Casanovas-Massana A, Campbell M, Tokuyama M, Vijayakumar P, et al.
640 Saliva or Nasopharyngeal Swab Specimens for Detection of SARS-CoV-2. The New England
641 journal of medicine. 2020.

642 22. Vogels CBF, Watkins AE, Harden CA, Brackney DE, Shafer J, Wang J, et al. SalivaDirect: A
643 Simplified and Flexible Platform to Enhance SARS-CoV-2 Testing Capacity. Med. 2020;1–18.

644 23. Buck MD, Poirier EZ, Cardoso A, Frederico B, Canton J, Barrell S, et al. SARS-CoV-2 detection
645 by a clinical diagnostic RT-LAMP assay. Wellcome Open Res. 2021;6:9.

646 24. Kellner MJ, Matl M, Ross JJ, Schnabl J, Handler D, Heinen R, et al. Head-to-head comparison
647 of direct-input RT-PCR and RT-LAMP against RT-qPCR on extracted RNA for rapid SARS-CoV-2
648 diagnostics. medRxiv [Internet]. 2021;2021.01.19.21250079. Available from:
649 https://doi.org/10.1101/2021.01.19.21250079

650 25. Ochert AS, Boulter AW, Birnbaum W, Johnson NW, Teo CG. Inhibitory effect of salivary fluids
651 on PCR: Potency and removal. PCR Methods Appl. 1994;3(6):365–8.

652 26. Wilson IG. Inhibition and facilitation of nucleic acid amplification. Appl Environ Microbiol.
653 1997;63(10):3741–51.

654 27. DHSC. Rapid evaluation of OptiGene RT-LAMP assay (direct and RNA formats). Department of
655 Health and Social Care. United Kingdom. 2020.

656 28. La Scola B, Le Bideau M, Andreani J, Hoang VT, Grimaldier C, Colson P, et al. Viral RNA load as
657 determined by cell culture as a management tool for discharge of SARS-CoV-2 patients from
658 infectious disease wards. Eur J Clin Microbiol Infect Dis. 2020;39(6):1059–61.

659 29. Bullard J, Dust K, Funk D, Strong JE, Alexander D, Garnett L, et al. Predicting Infectious Severe
660 Acute Respiratory Syndrome Coronavirus 2 From Diagnostic Samples. Clin Infect Dis.
661 2020;71(10):2663–6.

662 30. Wölfel R, Corman VM, Guggemos W, Seilmaier M, Zange S, Müller MA, et al. Virological
663 assessment of hospitalized patients with COVID-2019. Nature. 2020;581(7809):465–9.

664 31. Marc A, Kerioui M, Blanquart F, Bertrand J, Mitjà O, Corbacho-Monné M, et al. Quantifying

the relationship between SARS-CoV-2 viral load and infectiousness. medRxiv [Internet]. 2021;2021.05.07.21256341. Available from: https://doi.org/10.1101/2021.05.07.21256341

32. Fowler VL, Douglas A, Godfrey KM, Williams A, Beggs A, Kidd SP, et al. Critical evaluation of the methodology used by Wilson-Davies et al., (2020) entitled "Concerning the Optigene Direct LAMP assay, and it`s use in at-risk groups and hospital staff." J Infect. 2021;

33. Hanson KE, Barker AP, Hillyard DR, Gilmore N, Barrett JW, Orlandi RR, et al. Self-collected anterior nasal and saliva specimens versus healthcare worker-collected nasopharyngeal swabs for the molecular detection of SARS-CoV-2. J Clin Microbiol. 2020;(July):1–5.

34. Nikolai LA, Meyer CG, Kremsner PG, Velavan TP. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID- 19 . The COVID-19 resource centre is hosted on Elsevier Connect , the company ' s public news and information . 2020;(January).

35. Marks M, Millat P, Ouchi D, Roberts C, Alemany A, Corbacho-Monné M, et al. Transmission of COVID-19 in 282 clusters in Catalonia, Spain: A cohort study. medRxiv. 2020;3099(20):1–8.

36. Byambasuren O, Cardona M, Bell K, Clark J, McLaws ML, Glasziou P. Estimating the extent of asymptomatic COVID-19 and its potential for community transmission: Systematic review and meta-analysis. J Assoc Med Microbiol Infect Dis Canada. 2020;5(4):223–34.

37. Buitrago-Garcia D, Egli-Gany D, Counotte MJ, Hossmann S, Imeri H, Ipekci AM, et al. Occurrence and transmission potential of asymptomatic and presymptomatic SARSCoV-2 infections: A living systematic review and meta-analysis. PLoS Med. 2020;17(9):1–25.

38. Larremore DB, Wilder B, Lester E, Shehata S, Burke JM, Hay JA, et al. Test sensitivity is secondary to frequency and turnaround time for COVID-19 screening. Sci Adv. 2021;7(1):1–11.

39. Lee LYW, Rozmanowski S, Pang M, Charlett A, Anderson C, Hughes GJ, et al. An observational study of SARS-CoV-2 infectivity by viral load and demographic factors and the utility lateral flow devices to prevent transmission. Preprint.

40. Kissler SM, Fauver JR, Mack C, Tai C, Shiue KY, Kalinich CC, et al. Viral dynamics of SARS-CoV-2 infection and the predictive value of repeat testing. medRxiv. 2020;1–13.

41. Howson ELA, Armson B, Madi M, Kasanga CJ, Kandusi S, Sallu R, et al. Evaluation of Two Lyophilized Molecular Assays to Rapidly Detect Foot-and-Mouth Disease Virus Directly from Clinical Samples in Field Settings. Transbound Emerg Dis. 2017;64(3):861–71.

42. Armson B, Walsh C, Morant N, Fowler VL, Knowles NJ, Clark D. The development of two field-ready reverse transcription loop-mediated isothermal amplification assays for the rapid detection of Seneca Valley virus 1. Transbound Emerg Dis. 2019;66(1):497–504.

43. Horby P, Huntley C, Davies N, Edmunds J, Ferguson N, Medley G, et al. NERVTAG note on B.1.1.7 severity. 2021. p. 5–8.

44. Tegally H, Wilkinson E, Giovanetti M, Iranzadeh A, Fonseca V, Giandhari J, et al. Emergence and rapid spread of a new severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa. medRxiv. 2020;2.

45. Public Health England. COVID-19 (SARS-CoV-2) variants [Internet]. 11/06/2021. [cited 2021 Jun 17]. Available from: https://www.gov.uk/government/collections/new-sars-cov-2-variant

46. Vanaerschot M, Mann SA, Webber JT, Kamm J, Bell SM, Bell J, et al. Identification of a Polymorphism in the N Gene of SARS-CoV-2 That Adversely Impacts Detection by Reverse

Transcription-PCR. Caliendo AM, editor. J Clin Microbiol [Internet]. 2020 Dec 17;59(1):e02369-20. Available from: http://jcm.asm.org/content/59/1/e02369-20.abstract

47. Hasan MR, Sundararaju S, Manickam C, Mirza F, Al-Hail H, Lorenz S, et al. A Novel Point Mutation in the N Gene of SARS-CoV-2 May Affect the Detection of the Virus by Reverse Transcription-Quantitative PCR. McAdam AJ, editor. J Clin Microbiol [Internet]. 2021 Mar 19;59(4):e03278-20. Available from: http://jcm.asm.org/content/59/4/e03278-20.abstract

48. Artesi M, Bontems S, Göbbels P, Franckh M, Maes P, Boreux R, et al. A Recurrent Mutation at Position 26340 of SARS-CoV-2 Is Associated with Failure of the E Gene Quantitative Reverse Transcription-PCR Utilized in a Commercial Dual-Target Diagnostic Assay. Caliendo AM, editor. J Clin Microbiol [Internet]. 2020 Sep 22;58(10):e01598-20. Available from: http://jcm.asm.org/content/58/10/e01598-20.abstract

49. Wang R, Hozumi Y, Yin C, Wei G-W. Mutations on COVID-19 diagnostic targets. Genomics [Internet]. 2020;112(6):5204–13. Available from: https://www.sciencedirect.com/science/article/pii/S0888754320306546

50. Rausch JW, Capoferri AA, Katusiime MG, Patro SC, Kearney MF. Low genetic diversity may be an Achilles heel of SARS-CoV-2. Proc Natl Acad Sci [Internet]. 2020 Oct 6;117(40):24614 LP – 24616. Available from: http://www.pnas.org/content/117/40/24614.abstract

745 **Supplementary Information 1**

746

747 **Log reduction of SARS-CoV-2 for the heat and lysis steps used independently and sequentially**

748

749 We have determined the viral inactivation kinetics of the best sample preparation condition(s),
750 evaluating the effect of the heat and lysis steps on the viral inactivation of SARS-CoV-2 as determined
751 by infectivity assays. All inactivation experiments had to be conducted under Containment Level 3
752 Containment and as such was undertaken at APHA.

753 Heat inactivation experiments were conducted utilising high titre live SARS-CoV-2 virus spiked into
754 pools of saliva collected from APHA staff or in tissue culture supernatant (TCSN). Early experiments
755 demonstrated that saliva had a high toxicity for tissue culture cells, even after heat inactivation
756 demonstrating that toxicity was likely not enzymatic. As such further inactivation was undertaken on
757 live virus TSCN. These heat inactivation experiments demonstrated that SARS-Cov-2 was completely
758 inactivated by heating at 60°C (20 min plus) or ≥70°C (after 2, 5 or 10 min). Importantly optimised
759 RapiLyze Sample Lysis Buffer did not inactivate live virus on its own without a heat step. Further,
760 inactivation at 56°C was not 100% effective at shorter incubation times, and additionally showed a
761 loss in sensitivity following a 4 x 2-fold dilution (See table 2, P07102) at 10 and 30 minutes.

762

P07553 (C_T19)	1:2	1:4	1:8	1:16	1:36	1:64	1:128	1:256	1:512	1:1024	1:2048
VTM 1:1 into Lysis + 98˚C	D	D	D	D	D	D	D	D	D	D	D
	D	D	D	D	D	D	D	D	D	D	D
56˚C 10 mins pre-treat 1:1 VTM into lysis +98˚C	D	D	D	D	D	D	D	D	D	D	ND
	D	D	D	D	D	D	D	D	D	D	ND
56˚C 30 mins pre-treat 1:1 VTM into lysis +98˚C	D	D	D	D	D	D	D	ND	D	ND	ND
	D	D	D	D	D	D	D	D	ND	ND	ND

763 **Table 1:** Serial dilution of Patient VTM (C_T 19) 1:1 VTM into Lysis Buffer and 98°C heat treatment without and
764 without heat pre-treatment at 56°C for 10 or 30 minutes. **D** – RNA Detected, ND – RNA Not Detected, by Direct
765 RT-LAMP.

766

767

Patient VTM	P07553 (C_T 19)	P01127 (C_T 23.97)	P07102 (C_T 32.08)	P07392 (C_T 24.55)	P01071 (C_T 20.54)
VTM into 1:1 Lysis + 98˚C	D	D	D	D	D
	D	D	D	D	D
56˚C 30 mins pre-treat 1:1 VTM into lysis + 98˚C	D	D	ND	D	D
	D	D	ND	D	D

768 **Table 2:** Serial dilution of Patient VTM (C_T 19.00 to 32.08) 1:1 VTM into Lysis Buffer and 98°C heat treatment
769 without and without heat pre-treatment at 56°C for 10 or 30 minutes. **D** – RNA Detected, ND – RNA Not
770 Detected, by Direct RT-LAMP.

771

772 Interestingly, following optimisation of heat inactivation of live virus, pre-treatment of samples was
773 assessed to determine any impact of pre-treatment on assay sensitivity. A pre-treatment 70°C for 5
774 mins carried out on spiked samples prior to the proposed direct RT-LAMP assay has no effect on
775 subsequent LAMP or PCR results. Further experiments to test the effect of this pre-treatment on
776 positive patient samples will be carried out to confirm this result. It recommended that even if a pre-
777 treatment is effective in inactivating the virus that downstream processes are carried out in UV
778 hoods or with effective air-flow management to prevent cross contamination of the direct RT-LAMP
779 assay.

780 Comparison of Betapropiolactone (BPL) inactivated virus and live virus have demonstrated that BPL
781 inactivation has resulted in lower sensitivity of detection using direct RT-LAMP. BPL inactivated virus
782 is not an ideal substitute for live virus in spiking experiments. Any conclusions on assay sensitivity or
783 performance have therefore been drawn from experiments on spiking of live virus in TCSN or saliva
784 carried out in containment. Spiking of live virus into pooled saliva has demonstrated that direct
785 detection by RT-LAMP is possible in samples that give a C_T below 25/26 with extraction and PCR.

786

787

788 **Supplementary Information 2**

789

790 Sensitivity of the viral culture assay – 1 pfu/ml

791

792 The virus was diluted and a set number of pfu of virus (1000, 100, 10, 1 and 0.1) was added to duplicate
793 flasks containing Vero E6 cells and also AVL. Flasks were viewed for cpe. Supernatant from flasks that
794 showed no cpe were passed on twice. No cpe was observed in the flasks inoculated with 0.1 or 0.01
795 pfu after the two passes. AVL samples were taken from the flasks at the beginning and end of each
796 passage and the C_T values of the extracted nucleic acids shown below.

Number of pfu added to AVL/flask	E Gene Rt-PCR assay			Growth (cpe)	
	Ct value of dilution (AVL)	Baseline Mean Ct value from flasks	Final Mean Ct value from flasks	Flask 1	Flask 2
1000	19.64	25.0	12.2	+	+
100	22.65	28.4	11.8	+	+
10	26.00	31.8	11.9	+	+
1	28.73	35.0	12.6	+	+
0.1	32.11	37.6	37.3	-	-
0.01	34.43	39.8	37.7	-	-

797

798

799

800

801

802

803

804

805

806

807

808

809

810 **Supplementary Information 3**

811

812

813 **Table 5**. RT-LAMP results of time course from symptom onset of an individual with COVID-19.

Days post suspected exposure	Direct RT-LAMP			RNA RT-LAMP			RT-qPCR C_T		Observed Symptoms
	Tp 1	Tp 2	Result	Tp 1	Tp 2	Result	ORF1ab	N	
5	09:18	09:32	POS	11:09	10:50	POS	23.31	26.47	Onset: Sore throat. Blocked nose. Headache. Lack of appetite. Fever.
6	10:32	11:34	POS	10:34	10:40	POS	21.16	24.03	Sore throat. Headache. Restless sleeping. Tired
7	10:19	13:40	POS	11:39	09:59	POS	24.47	27.30	Headache. Restless sleeping. Tired. Loss of smell and taste.
9	09:31	09:14	POS	08:35	09:37	POS	28.55	31.89	Tired. Loss of smell and taste.
11	13:14	11:47	POS	16:44	16:39	POS	26.44	29.06	Tired. Loss of smell and taste.
12	09:10	10:09	POS	12:42	12:01	POS	26.13	29.19	Tired. Improvement in smell and taste.
13	NEG	NEG	NEG	14:06	12:56	POS	28.16	30.62	Significant improvement in all symptoms
14	NEG	NEG	NEG	NEG	NEG	NEG	38.05	40.73	None
16	NEG	NEG	NEG	NEG	NEG	NEG	36.11	NEG	None
17	NEG	NEG	NEG	NEG	NEG	NEG	NEG	NEG	None

814 Time to positivity in minutes [Tp]; Cycle Threshold [C_T]; Negative [NEG]; positive [POS]

815

816

817